Gutin P H, Hosobuchi Y, Phillips T L, Stupar T A
Cancer Treat Rep. 1981;65 Suppl 2:103-6.
Eighteen patients harboring untreated, inaccessible, slow-growing tumors or recurrent malignant primary or metastatic brain tumors were treated by the stereotactic implantation of permanent or removable radioactive seeds (192Ir, 198Au, 125I). Seed strength was selected to deliver 10,000-12,000 rad to the tumor's periphery for 192Ir, 9000-12,000 rad for 125I, and 4000-7500 rad for 198Au. Three of six patients implanted with 192Ir seeds had objective responses for 2, 8, and 12 months, and a fourth stabilized for 20 months. Five of 9 patients treated with 198Au were evaluable, three of whom responded for 3, 5, and 20 months. Two patients who received 125I have been evaluated to date and are early failures. Two patients who received 125I have been evaluated to date and are early failures. Because of its higher dose rate 198Au is superior for the faster-growing malignant tumors; but because 125I is easier to shield, 125I seeds with greater activity are being developed for evaluation.
18例患有未经治疗、难以接近、生长缓慢的肿瘤或复发性恶性原发性或转移性脑肿瘤的患者接受了永久性或可移除放射性种子（192铱、198金、125碘）的立体定向植入治疗。种子强度的选择是为了使192铱在肿瘤周边给予10000 - 12000拉德剂量，125碘给予9000 - 12000拉德剂量，198金给予4000 - 7500拉德剂量。6例植入192铱种子的患者中有3例出现客观缓解，缓解时间分别为2个月、8个月和12个月，第4例病情稳定20个月。9例接受198金治疗的患者中有5例可评估，其中3例缓解时间为3个月、5个月和20个月。迄今为止，2例接受125碘治疗的患者已接受评估，均为早期失败者。迄今为止，2例接受125碘治疗的患者已接受评估，均为早期失败者。由于198金剂量率较高，对于生长较快的恶性肿瘤更具优势；但由于125碘更容易屏蔽，目前正在研发活性更高的125碘种子用于评估。
